<DOC>
	<DOCNO>NCT01185886</DOCNO>
	<brief_summary>RATIONALE : Collecting store sample tumor tissue , blood , bone marrow , body fluid patient test laboratory collect information patient 's health treatment may help doctor learn cancer help study cancer future . Studying sample laboratory may help doctor learn change occur DNA identify biomarkers related cancer . It may also help doctor predict patient respond treatment . PURPOSE : This research study collect look blood tissue sample child newly diagnose acute lymphoblastic leukemia .</brief_summary>
	<brief_title>Study Blood Tissue Samples Children With Newly Diagnosed Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Collect clinical data parallel biological data sample child newly diagnose acute lymphoblastic leukemia biobanking , use part biobanked material perform specific translational project achieve objectives II-IV . - To identify new prognostic factor ( e.g. , minimal-residual disease [ MRD ] significance small subgroup , miRNAs expression profile , PAX5 mutation , genetic abnormality T-cell acute lymphoblastic leukemia [ T-ALL ] , RAS pathway activation ) future therapeutic target child newly diagnose acute lymphoblastic leukemia . - To identify leukemia cell genetic alteration ( e.g. , mutation T-ALL miRNA expression B-cell acute lymphoblastic leukemia [ B-ALL ] ) relate molecular pathway ( e.g. , RAS pathway ) underlie leukemogenesis . - To identify patient pharmacogenetic polymorphism impact individual response corticosteroid part standard therapy investigate prognostic significance . OUTLINE : This prospective observational biobanking study . Patients undergo clinical evaluation , laboratory test , image periodically . Data collect , , first-line standard therapy . Clinical data collect patient parallel biological data sample . Biological sample partly use perform specific translational research ( TR ) project . Remaining biological material store future research . The following TR project perform biological sample study . Biological sample analyze allele-specific amplification Ig/TCR clonal rearrangement quantify minimal-residual disease ( MRD ) via real-time PCR ( TR1 Project ) ; miRNA expression via qPCR ( TR 2 Project ) ; detection main point mutation via high-resolution melt PCR ( TR 3 Project ) ; genetic polymorphism via real-time TaqMan allelic-discrimination method ( TR 4 Project ) ; clinical significance genetic abnormality via quantitative real-time RT-PCR , direct sequencing , fluorescence situ hybridization ( TR 5 Project ) ; RAS pathway activation via single-nucleotide polymorphism ( SNP ) analysis gene-expression analysis ( TR 6 Project ) .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose acute lymphoblastic leukemia ( ALL ) , meet follow criterion : FAB L1 L2 morphology ( immunophenotype ) acute leukemias ambiguous lineage ( include biphenotypic bilineal acute lymphoblastic leukemia ) Patients mature Bcell acute lymphoblastic leukemia ( BALL ) ( FAB L3 morphology immunophenotypical mature B phenotype BALL document presence karyotype ( 8 ; 14 ) , ( 2 ; 8 ) ( 8 ; 22 ) breakpoints mature BALL ) exclude study Patients must also meet follow criterion participate individual translational research ( TR ) project : TR 1 project ( MRD prognostic significance small ALL subgroup ) : All patient , categorize accord response prephase ( &lt; &gt; 1,000 peripheral blasts/mmÂ³ day 8 ) minimalresidual disease ( MRD ) level end induction therapy iAmp ( 21q ) detect presentation Hypodiploidy detect presentation karyotype and/or fluorescence situ hybridization ( FISH ) and/or DNA index TR 2 project ( miRNAs expression pediatric ALL ) : Initially , averagerisk 1 ( AR1 ) patient In second stage , analysis might extend lowrisk patient still show treatment failure highrisk ALL patient TR 3 project ( Prognostic value newly describe mutation childhood BALL ) Initially , Bcell precursor ALL patient TR 4 project ( Pharmacogenetics response prephase induction therapy ) : All ALL patient TR 5 project ( Clinical significance genetic abnormality childhood TALL ) : All patient Tcell ALL , define expression Tcell surface antigens TR 6 project ( RAS pathway activation childhood BALL ) : All patient Blineage ALL Patients Philadelphiachromosome positive ALL ( document presence ( 9 ; 22 ) ( q34 ; q11 ) and/or BCR/ABL fusion transcript ) eligible Scheduled receive therapy per institutional standard practice start therapy ( except maximum 7 day systemic corticosteroid prior diagnosis ) May register study PATIENT CHARACTERISTICS : No psychological , familial , sociological , geographical condition potentially hamper participation study protocol followup schedule Patients Down syndrome eligible PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>untreated childhood acute lymphoblastic leukemia</keyword>
	<keyword>L1 childhood acute lymphoblastic leukemia</keyword>
	<keyword>L2 childhood acute lymphoblastic leukemia</keyword>
	<keyword>B-cell childhood acute lymphoblastic leukemia</keyword>
	<keyword>T-cell childhood acute lymphoblastic leukemia</keyword>
	<keyword>stage I childhood lymphoblastic lymphoma</keyword>
	<keyword>stage II childhood lymphoblastic lymphoma</keyword>
	<keyword>stage III childhood lymphoblastic lymphoma</keyword>
	<keyword>stage IV childhood lymphoblastic lymphoma</keyword>
	<keyword>Philadelphia chromosome positive childhood precursor acute lymphoblastic leukemia</keyword>
</DOC>